Abstract
A brief overview of the general, retrometabolic drug design principles, including soft drug and chemical delivery system design, is presented. Selected recent developments within these fields are also summarized, including results related to the design of soft bufuralol and amiodarone analogues, to the airway activity of loteprednol etabonate, a soft corticosteroid, and to the brain targeted delivery of some neuropeptides.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
